BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Fujimoto Y, Kaji K, Nishimura N, Enomoto M, Murata K, Takeda S, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. World J Gastroenterol 2021; 27(48): 8323-8342 [PMID: 35068872 DOI: 10.3748/wjg.v27.i48.8323]
URL: https://www.wjgnet.com/1007-9327/full/v27/i48/8323.htm
Number Citing Articles
1
Nima Zafari, Mahla Velayati, Mostafa Fahim, Mina Maftouh, Ghazaleh Pourali, Majid Khazaei, Mohammadreza Nassiri, Seyed Mahdi Hassanian, Majid Ghayour-Mobarhan, Gordon A. Ferns, Mohammad Ali Kiani, Amir Avan. Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: Molecular mechanisms, biomarkers, and therapeutic prospectiveLife Sciences 2022; 305: 120760 doi: 10.1016/j.lfs.2022.120760
2
Masahide Enomoto, Kosuke Kaji, Norihisa Nishimura, Yuki Fujimoto, Koji Murata, Soichi Takeda, Yuki Tsuji, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitisDigestive and Liver Disease 2022;  doi: 10.1016/j.dld.2022.04.012